The effect of supplemental Saccharomyces boulardii plus standard triple therapy on Helicobacter pylori in children Original paper

In this meta-analysis of randomized controlled trials, supplementation with Saccharomyces boulardii in combination with standard triple therapy was more effective than standard triple therapy alone in increasing the Helicobacter pylori eradication rate.

This Study Summary was published on February 6, 2024.

Quick Summary

In this meta-analysis of randomized controlled trials, supplementation with Saccharomyces boulardii in combination with standard triple therapy was more effective than standard triple therapy alone in increasing the Helicobacter pylori eradication rate.

What was studied?

The effect of supplementation with Saccharomyces boulardii (S. boulardii) in combination with standard triple therapy (STT) on the Helicobacter pylori (H. pylori) eradication rate (primary outcome). The secondary outcome was the incidence of adverse events.

The H. pylori eradication rate was measured using the urea breath test, rapid urease test, histology (examination of cell samples), stool antigen test, or bacterial culture.

Who was studied?

A total of 2,156 participants (ages 3–18) who received treatment for the first time for H. pylori infection.

How was it studied?

A meta-analysis of randomized controlled trials was performed. The studies were conducted in Romania (1 study) and China (14 studies).

The participants received either a supplement containing S. boulardii (average dosage of 500 mg/day for 14 days) in combination with STT (i.e., omeprazole, amoxicillin, clarithromycin) or STT alone.

What were the results?

Supplementation with S. boulardii in combination with STT was more effective than STT alone in increasing (improving) the H. pylori eradication rate in children.

The combination of S. boulardii and STT also had a lower incidence of total adverse events and specific adverse events (i.e., diarrhea, nausea, vomiting, constipation, abdominal pain, abdominal distention, epigastric discomfort, poor appetite, and stomatitis) compared to STT alone.

Anything else I need to know?

The quality of evidence was deemed low for the H. pylori eradication rate and low to medium for the incidence of all adverse events. Additionally, the presence of publication bias could not be excluded.

Finally, it’s worth noting that most studies in this meta-analysis were conducted in China, and therefore, additional research in Western countries is required before generalizing these results.

This Study Summary was published on February 6, 2024.